Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 258

1.

Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation.

Alderuccio JP, Zhao W, Desai A, Ramdial J, Gallastegui N, Kimble E, de la Fuente MI, Husnain M, Rosenblatt JD, Alencar AJ, Schatz JH, Moskowitz CH, Chapman JR, Vega F, Reis IM, Lossos IS.

Am J Hematol. 2019 May;94(5):585-596. doi: 10.1002/ajh.25446. Epub 2019 Mar 10.

PMID:
30784098
2.

Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma.

de la Fuente MI, Alderuccio JP, Reis IM, Omuro A, Markoe A, Echegaray JJ, Davis JL, Harbour JW, Lossos IS.

Am J Hematol. 2019 Apr;94(4):455-460. doi: 10.1002/ajh.25414. Epub 2019 Feb 4.

PMID:
30663807
3.

Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.

Hill BT, Nastoupil L, Winter AM, Becnel MR, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Fakhri B, Reddy P, Smith SD, Mukhija D, Jagadeesh D, Desai A, Alderuccio JP, Lossos IS, Mehra P, Portell CA, Goldman ML, Calzada O, Cohen JB, Hussain MJ, Ghosh N, Caimi P, Tiutan T, Martin P, Kodali A, Evens AM, Kahl BS.

Br J Haematol. 2019 Feb;184(4):524-535. doi: 10.1111/bjh.15720. Epub 2018 Dec 21.

PMID:
30575016
4.

Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma.

Mackrides N, Chapman J, Larson MC, Ramos JC, Toomey N, Lin P, Maurer MJ, Rafaelle M, Tan Y, Ikpatt O, Syrbu S, Ansell SM, Habermann TM, Link BK, Feldman AL, Lossos IS, Cerhan JR, Vega F.

Am J Hematol. 2019 Feb;94(2):E62-E64. doi: 10.1002/ajh.25357. Epub 2018 Dec 5. No abstract available.

PMID:
30474261
5.

CD4+/CD8+ immunophenotype switching as a marker for intraocular and CNS involvement in mycosis fungoides.

Husnain M, Mackrides N, Vega F, Paez-Escamilla M, Markoe AM, Harbour JW, Lossos IS.

Leuk Lymphoma. 2019 May;60(5):1308-1311. doi: 10.1080/10428194.2018.1526376. Epub 2018 Nov 14. No abstract available.

PMID:
30424702
6.

DA-EPOCH-R for Adult Burkitt's Lymphoma: Pros and Cons.

Alderuccio JP, Lossos IS.

J Oncol Pract. 2018 Nov;14(11):676-678. doi: 10.1200/JOP.18.00624. No abstract available.

PMID:
30423268
7.

Splenic B-Cell Lymphomas with Diffuse Cyclin D1 Protein Expression and Increased Prolymphocytic Cells: A Previously Unrecognized Diagnostic Pitfall.

Algashaamy K, Tan Y, Mackrides N, Alencar A, Peng JH, Rosenblatt J, Alderuccio JP, Lossos IS, Vega F, Chapman J.

Case Rep Hematol. 2018 Sep 27;2018:5761953. doi: 10.1155/2018/5761953. eCollection 2018.

8.

Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution.

Alderuccio JP, Zhao W, Desai A, Gallastegui N, Ramdial J, Kimble E, de la Fuente MI, Rosenblatt JD, Chapman JR, Vega F, Reis IM, Lossos IS.

J Clin Oncol. 2018 Oct 12:JCO1800138. doi: 10.1200/JCO.18.00138. [Epub ahead of print]

PMID:
30312133
9.

Intracytoplasmic azurophilic inclusions in prolymphocytes.

Mackrides N, Lossos IS, Vega F.

Int J Hematol. 2018 Dec;108(6):565. doi: 10.1007/s12185-018-2541-0. Epub 2018 Oct 9. No abstract available.

PMID:
30302738
10.

Smoothened stabilizes and protects TRAF6 from degradation: A novel non-canonical role of smoothened with implications in lymphoma biology.

Qu C, Kunkalla K, Vaghefi A, Frederiksen JK, Liu Y, Chapman JR, Blonska M, Bernal-Mizrachi L, Alderuccio JP, Lossos IS, Landgraf R, Vega F.

Cancer Lett. 2018 Nov 1;436:149-158. doi: 10.1016/j.canlet.2018.08.020. Epub 2018 Aug 27.

PMID:
30165192
11.

PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival.

Lu X, Fernando TM, Lossos C, Yusufova N, Liu F, Fontán L, Durant M, Geng H, Melnick J, Luo Y, Vega F, Moy V, Inghirami G, Nimer S, Melnick AM, Lossos IS.

Blood. 2018 Nov 8;132(19):2026-2039. doi: 10.1182/blood-2018-02-831438. Epub 2018 Aug 6.

PMID:
30082494
12.

Lmo2 expression defines tumor cell identity during T-cell leukemogenesis.

García-Ramírez I, Bhatia S, Rodríguez-Hernández G, González-Herrero I, Walter C, González de Tena-Dávila S, Parvin S, Haas O, Woessmann W, Stanulla M, Schrappe M, Dugas M, Natkunam Y, Orfao A, Domínguez V, Pintado B, Blanco O, Alonso-López D, De Las Rivas J, Martín-Lorenzo A, Jiménez R, García Criado FJ, García Cenador MB, Lossos IS, Vicente-Dueñas C, Borkhardt A, Hauer J, Sánchez-García I.

EMBO J. 2018 Jul 13;37(14). pii: e98783. doi: 10.15252/embj.201798783. Epub 2018 Jun 7.

13.

Rapid complete response to blinatumomab as a successful bridge to allogeneic stem cell transplantation in a case of refractory Richter syndrome.

Alderuccio JP, Mackrides N, Chapman JR, Vega F, Lossos IS.

Leuk Lymphoma. 2019 Jan;60(1):230-233. doi: 10.1080/10428194.2018.1461862. Epub 2018 May 10. No abstract available.

PMID:
29745744
14.

Frontline brentuximab vedotin in breast implant-associated anaplastic large-cell lymphoma.

Alderuccio JP, Desai A, Yepes MM, Chapman JR, Vega F, Lossos IS.

Clin Case Rep. 2018 Feb 16;6(4):634-637. doi: 10.1002/ccr3.1382. eCollection 2018 Apr.

15.

MiR-181 family-specific behavior in different cancers: a meta-analysis view.

Pop-Bica C, Pintea S, Cojocneanu-Petric R, Del Sal G, Piazza S, Wu ZH, Alencar AJ, Lossos IS, Berindan-Neagoe I, Calin GA.

Cancer Metastasis Rev. 2018 Mar;37(1):17-32. doi: 10.1007/s10555-017-9714-9.

PMID:
29327093
16.

Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.

Pilichowska M, Pittaluga S, Ferry JA, Hemminger J, Chang H, Kanakry JA, Sehn LH, Feldman T, Abramson JS, Kritharis A, Hernandez-Ilizaliturri FJ, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA, Jagadeesh D, Woda B, Gupta GK, Gascoyne RD, Jaffe ES, Evens AM.

Blood Adv. 2017 Dec 11;1(26):2600-2609. doi: 10.1182/bloodadvances.2017009472. eCollection 2017 Dec 12.

17.

Decreased survival in hepatitis C patients with monomorphic post-transplant lymphoproliferative disorder after liver transplantation treated with frontline immunochemotherapy.

Alderuccio JP, Stefanovic A, Dammrich D, Chapman JR, Vega F, Selvaggi G, Tzakis A, Lossos IS.

Leuk Lymphoma. 2018 Sep;59(9):2096-2104. doi: 10.1080/10428194.2017.1413187. Epub 2017 Dec 18.

PMID:
29252057
18.

KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas.

Kunder CA, Roncador G, Advani RH, Gualco G, Bacchi CE, Sabile JM, Lossos IS, Nie K, Tibshirani RJ, Green MR, Alizadeh AA, Natkunam Y.

Am J Clin Pathol. 2017 Nov 20;148(6):465-476. doi: 10.1093/ajcp/aqx099.

19.

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).

Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, Hamadani M, Ghosh N, Reeder CB, Barnett E, Bravo MC, Martin P.

J Hematol Oncol. 2017 Nov 2;10(1):171. doi: 10.1186/s13045-017-0537-5.

20.

Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.

Guo X, Koff JL, Moffitt AB, Cinar M, Ramachandiran S, Chen Z, Switchenko JM, Mosunjac M, Neill SG, Mann KP, Bagirov M, Du Y, Natkunam Y, Khoury HJ, Rossi MR, Harris W, Flowers CR, Lossos IS, Boise LH, Dave SS, Kowalski J, Bernal-Mizrachi L.

Oncogene. 2017 Jul 20;36(29):4224-4232. doi: 10.1038/onc.2017.90. Epub 2017 Apr 3.

PMID:
28368397
21.

Hepatosplenic T-cell lymphoma associated with membranoproliferative glomerulonephritis.

Wu SC, Chapman JR, Vega F, Abrahams N, Lossos IS, Alderuccio JP.

Leuk Lymphoma. 2017 Nov;58(11):2734-2737. doi: 10.1080/10428194.2017.1307358. Epub 2017 Mar 28. No abstract available.

PMID:
28351190
22.

Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity.

Bhatt S, Parvin S, Zhang Y, Cho HM, Kunkalla K, Vega F, Timmerman JM, Shin SU, Rosenblatt JD, Lossos IS.

Blood. 2017 Apr 20;129(16):2246-2256. doi: 10.1182/blood-2016-09-738211. Epub 2017 Jan 30.

23.

The Genetic Basis of Hepatosplenic T-cell Lymphoma.

McKinney M, Moffitt AB, Gaulard P, Travert M, De Leval L, Nicolae A, Raffeld M, Jaffe ES, Pittaluga S, Xi L, Heavican T, Iqbal J, Belhadj K, Delfau-Larue MH, Fataccioli V, Czader MB, Lossos IS, Chapman-Fredricks JR, Richards KL, Fedoriw Y, Ondrejka SL, Hsi ED, Low L, Weisenburger D, Chan WC, Mehta-Shah N, Horwitz S, Bernal-Mizrachi L, Flowers CR, Beaven AW, Parihar M, Baseggio L, Parrens M, Moreau A, Sujobert P, Pilichowska M, Evens AM, Chadburn A, Au-Yeung RK, Srivastava G, Choi WW, Goodlad JR, Aurer I, Basic-Kinda S, Gascoyne RD, Davis NS, Li G, Zhang J, Rajagopalan D, Reddy A, Love C, Levy S, Zhuang Y, Datta J, Dunson DB, Davé SS.

Cancer Discov. 2017 Apr;7(4):369-379. doi: 10.1158/2159-8290.CD-16-0330. Epub 2017 Jan 25.

24.

Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas.

Abate F, da Silva-Almeida AC, Zairis S, Robles-Valero J, Couronne L, Khiabanian H, Quinn SA, Kim MY, Laginestra MA, Kim C, Fiore D, Bhagat G, Piris MA, Campo E, Lossos IS, Bernard OA, Inghirami G, Pileri S, Bustelo XR, Rabadan R, Ferrando AA, Palomero T.

Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):764-769. doi: 10.1073/pnas.1608839114. Epub 2017 Jan 6.

25.

Epstein-Barr virus-positive follicular lymphoma.

Mackrides N, Campuzano-Zuluaga G, Maque-Acosta Y, Moul A, Hijazi N, Ikpatt FO, Levy R, Verdun RE, Kunkalla K, Natkunam Y, Lossos IS, Vega F, Chapman J.

Mod Pathol. 2017 Apr;30(4):519-529. doi: 10.1038/modpathol.2016.214. Epub 2016 Dec 16.

26.

Long-term course of patients with primary ocular adnexal MALT lymphoma: a large single-institution cohort study.

Desai A, Joag MG, Lekakis L, Chapman JR, Vega F, Tibshirani R, Tse D, Markoe A, Lossos IS.

Blood. 2017 Jan 19;129(3):324-332. doi: 10.1182/blood-2016-05-714584. Epub 2016 Oct 27.

27.

Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences.

de la Fuente MI, Haggiagi A, Moul A, Young RJ, Sidani C, Markoe A, Vega F, DeAngelis LM, Lossos IS.

Leuk Lymphoma. 2017 Apr;58(4):882-888. doi: 10.1080/10428194.2016.1218006. Epub 2016 Sep 21.

28.

Interleukin 21 - its potential role in the therapy of B-cell lymphomas.

Bhatt S, Sarosiek KA, Lossos IS.

Leuk Lymphoma. 2017 Jan;58(1):17-29. Epub 2016 Jul 13. Review.

PMID:
27405876
29.

Characteristics and outcomes of lymphoblastic lymphoma - the University of Miami experience.

Alderuccio JP, Amarapurkar P, Chapman JR, Vega F, Lossos IS.

Leuk Lymphoma. 2017 Jan;58(1):195-198. Epub 2016 Jun 2. No abstract available.

PMID:
27252116
30.

Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma.

Matthews JM, Bhatt S, Patricelli MP, Nomanbhoy TK, Jiang X, Natkunam Y, Gentles AJ, Martinez E, Zhu D, Chapman JR, Cortizas E, Shyam R, Chinichian S, Advani R, Tan L, Zhang J, Choi HG, Tibshirani R, Buhrlage SJ, Gratzinger D, Verdun R, Gray NS, Lossos IS.

Blood. 2016 Jul 14;128(2):239-48. doi: 10.1182/blood-2016-02-696856. Epub 2016 May 5.

31.

GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo.

Healy JA, Nugent A, Rempel RE, Moffitt AB, Davis NS, Jiang X, Shingleton JR, Zhang J, Love C, Datta J, McKinney ME, Tzeng TJ, Wettschureck N, Offermanns S, Walzer KA, Chi JT, Rasheed SA, Casey PJ, Lossos IS, Dave SS.

Blood. 2016 Jun 2;127(22):2723-31. doi: 10.1182/blood-2015-07-659938. Epub 2016 Mar 17.

32.

miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis.

Kozloski GA, Jiang X, Bhatt S, Ruiz J, Vega F, Shaknovich R, Melnick A, Lossos IS.

Blood. 2016 Jun 9;127(23):2856-66. doi: 10.1182/blood-2015-11-680462. Epub 2016 Mar 3.

33.

Active IKKβ promotes the stability of GLI1 oncogene in diffuse large B-cell lymphoma.

Agarwal NK, Kim CH, Kunkalla K, Konno H, Tjendra Y, Kwon D, Blonska M, Kozloski GA, Moy VT, Verdun RE, Barber GN, Lossos IS, Vega F.

Blood. 2016 Feb 4;127(5):605-15. doi: 10.1182/blood-2015-07-658781. Epub 2015 Nov 24.

34.

Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma.

Bhatt S, Matthews J, Parvin S, Sarosiek KA, Zhao D, Jiang X, Isik E, Letai A, Lossos IS.

Blood. 2015 Sep 24;126(13):1555-64. doi: 10.1182/blood-2015-01-624585. Epub 2015 Jul 20.

35.

Novel Use of Endoscopic Clips as Fiducials for Radiotherapy in Small Bowel Lymphoma.

Mendez V, Martinez FJ, Soriano FB, Markoe AM, Lossos IS, Saigal K, Sussman DA.

ACG Case Rep J. 2014 Jul 8;1(4):184-6. doi: 10.14309/crj.2014.46. eCollection 2014 Jul.

36.

LymphomiRs: microRNAs with regulatory roles in lymphomas.

Kozloski GA, Lossos IS.

Curr Opin Hematol. 2015 Jul;22(4):362-8. doi: 10.1097/MOH.0000000000000157. Review.

PMID:
26049758
37.

Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.

Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Fabregas JC, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA.

Am J Hematol. 2015 Sep;90(9):778-83. doi: 10.1002/ajh.24082.

38.

Gene expression analysis of plasmablastic lymphoma identifies downregulation of B-cell receptor signaling and additional unique transcriptional programs.

Chapman J, Gentles AJ, Sujoy V, Vega F, Dumur CI, Blevins TL, Bernal-Mizrachi L, Mosunjac M, Pimentel A, Zhu D, Lossos IS.

Leukemia. 2015 Nov;29(11):2270-3. doi: 10.1038/leu.2015.109. Epub 2015 Apr 24. No abstract available.

PMID:
25921246
39.

A roadmap for discovery and translation in lymphoma.

Weinstock DM, Dalla-Favera R, Gascoyne RD, Leonard JP, Levy R, Lossos IS, Melnick AM, Nowakowski GS, Press OW, Savage KJ, Shipp MA, Staudt LM.

Blood. 2015 Mar 26;125(13):2175-7. doi: 10.1182/blood-2015-01-623777. No abstract available.

40.

Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma.

Hosein PJ, Sandoval-Sus JD, Goodman D, Arteaga AG, Reis I, Hoffman J, Stefanovic A, Rosenblatt JD, Lossos IS.

Am J Hematol. 2015 Jun;90(6):E111-6. doi: 10.1002/ajh.23996. Epub 2015 Apr 2.

41.

Chlamydophila psittaci-negative ocular adnexal marginal zone lymphomas express self polyreactive B-cell receptors.

Zhu D, Bhatt S, Lu X, Guo F, Veelken H, Hsu DK, Liu FT, Alvarez Cubela S, Kunkalla K, Vega F, Chapman-Fredricks JR, Lossos IS.

Leukemia. 2015 Jul;29(7):1587-99. doi: 10.1038/leu.2015.39. Epub 2015 Feb 13.

PMID:
25676418
42.

HGAL localization to cell membrane regulates B-cell receptor signaling.

Lu X, Sicard R, Jiang X, Stockus JN, McNamara G, Abdulreda M, Moy VT, Landgraf R, Lossos IS.

Blood. 2015 Jan 22;125(4):649-57. doi: 10.1182/blood-2014-04-571331. Epub 2014 Nov 7.

43.

Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-κB pathway.

Ramachandiran S, Adon A, Guo X, Wang Y, Wang H, Chen Z, Kowalski J, Sunay UR, Young AN, Brown T, Mar JC, Du Y, Fu H, Mann KP, Natkunam Y, Boise LH, Saavedra HI, Lossos IS, Bernal-Mizrachi L.

Int J Cancer. 2015 May 15;136(10):2341-51. doi: 10.1002/ijc.29301. Epub 2014 Nov 11.

44.

Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma.

Lossos IS, Fabregas JC, Koru-Sengul T, Miao F, Goodman D, Serafini AN, Hosein PJ, Stefanovic A, Rosenblatt JD, Hoffman JE.

Leuk Lymphoma. 2015 Jun;56(6):1750-5. doi: 10.3109/10428194.2014.975801. Epub 2014 Nov 20.

PMID:
25315074
45.

Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.

Green MR, Vicente-Dueñas C, Romero-Camarero I, Long Liu C, Dai B, González-Herrero I, García-Ramírez I, Alonso-Escudero E, Iqbal J, Chan WC, Campos-Sanchez E, Orfao A, Pintado B, Flores T, Blanco O, Jiménez R, Martínez-Climent JA, Criado FJ, Cenador MB, Zhao S, Natkunam Y, Lossos IS, Majeti R, Melnick A, Cobaleda C, Alizadeh AA, Sánchez-García I.

Nat Commun. 2014 Jun 2;5:3904. doi: 10.1038/ncomms4904.

46.

Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and/or 13q14.

Chapman-Fredricks J, Sandoval-Sus J, Vega F, Lossos IS.

Ann Diagn Pathol. 2014 Aug;18(4):214-9. doi: 10.1016/j.anndiagpath.2014.03.006. Epub 2014 Apr 13.

PMID:
24852242
47.

Rosai-Dorfman disease of the central nervous system: report of 6 cases and review of the literature.

Sandoval-Sus JD, Sandoval-Leon AC, Chapman JR, Velazquez-Vega J, Borja MJ, Rosenberg S, Lossos A, Lossos IS.

Medicine (Baltimore). 2014 May;93(3):165-75. doi: 10.1097/MD.0000000000000030. Review.

48.

Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study.

Evens AM, Smith MR, Lossos IS, Helenowski I, Millenson M, Winter JN, Rosen ST, Gordon LI.

Br J Haematol. 2014 Aug;166(4):514-20. doi: 10.1111/bjh.12915. Epub 2014 Apr 25.

PMID:
24761968
49.

Lymphoma associated hemophagocytic syndrome: it's going viral.

Hoffman J, Lossos IS.

Leuk Lymphoma. 2014 Sep;55(9):1964-5. doi: 10.3109/10428194.2014.914200. Epub 2014 Jun 16. No abstract available.

PMID:
24738941
50.

The DNA methylome: a novel biomarker.

Lossos IS.

Blood. 2014 Mar 13;123(11):1627-8. doi: 10.1182/blood-2014-01-548586. No abstract available.

Supplemental Content

Loading ...
Support Center